Research and Clinical Trials

Title  
TG Therapeutics UTX-TGR-204: A Multi-Center, Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304
Brief Description  
Primary: To determine the overall response rate (ORR) defined as the sum of complete responses (CR) and partial responses (PR). Secondary: To evaluate the progression-free survival (PFS) and duration of response (DOR). TO evaluate the percent of patients that achieve MRD negativity. TO evaluate the safety of ublituximab in combination with TGR-1202.
Who may be Eligible  
Please contact us for eligibility criteria.
Speciality/Disorder  
Leukemia, other
Status  
OPEN
Start Date  
12/05/2016
IRB Number  
00014332
Principal Investigator  
Jacobs, Ryan
Contact Name  
Sally P Ware

For More Information, Contact  Sally  P, Ware
Phone:  980-442-2030 Fax:    
Email:  Sally.Ware@carolinashealthcare.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, 28204
Close